Circio Holding ASA is a biotechnology company, which engages in developing novel circular RNA and immunotherapy medicines. It focuses on developing a cancer vaccine, TG01, targeting KRAS driver mutations. The company was founded on October 1, 2010 and is headquartered in Lysaker, Norway.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company